Clinical trial · Interventional
Immunological Response After Ablative Therapy in the Liver
Comparison of Immunological Response After Microwave Ablation and Irreversible Electroporation of Hepatocellular Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): poor recruitment
Summary
Brief summary (as posted)
Local ablative treatment of Hepatocellular Carcinoma is performed primary on patients not eligible for liver transplant or liver resection. At our Hospital two different methods are used: Microwave ablation, where the tumor cells are heated up and killed, and Irreversible electroporation, where the tumor cells are exposed to an electrical field and nano-pores are formed in the cell membranes and the cells go into apoptosis (programed cell death). Previous studies have shown effects on the immune system after ablative therapies. The purpose of this study is to compare the immunological response after the wo different methods of killing the tumor cells.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Immune Response | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Irreversible electroporation | Device | — | UNRESOLVED |
| Microwave ablation | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- OTHER
- label
- Microwave ablation
- description
- 20 patients will be treated with microwave ablation
- interventionNames
- Device: Microwave ablation
- type
- OTHER
- label
- Irreversible electroporation
- description
- 20 patients will be treated with irreversible electroporation
- interventionNames
- Device: Irreversible electroporation
Primary outcomes (1)
- measure
- Immunological response
- timeFrame
- Change from baseline (morning of the procedure) measured at post operative day 1,7, 28 and 90
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Hepatocellular carcinoma, maximum 3 lesions, maximum 30 mm in any cross section diameter * Physically fit to undergo general anaesthesia * Fully understand swedish instructions regarding the study Exclusion Criteria: * Atrial fibrillation (for irreversible electroporation) * Pacemaker (for irreversible electroporation) * \>3 lesions * \> 30 mm in any cross section diameter
References
Publications (0)
Data not yet available